Test Price
3,000 AED✅ Home Collection Available
Myeloid Tumor Panel Genetic Test in UAE | 3000 AED | 2026 DHA Guidelines
تحليل لوحة الأورام النخاعية الجيني الشامل في الإمارات | 3000 درهم | معتمد من هيئة الصحة بدبي
Executive Summary & Patient Guarantee
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity achieved via ISO 9001:2015 Accredited NGS Processing, ensuring clinically actionable insights for your oncologist.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection, with VIP Mobile Phlebotomy available 8 AM to 11 PM, 7 days a week.
- Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance from a certified genetic counselor to aid in result interpretation, bridging the gap between complex genomics and patient understanding.
- Insurance Support: Direct Billing Verification and pre-authorization assistance via WhatsApp: +971 54 548 8731.
الملخص التنفيذي: يوفر اختبار لوحة الأورام النخاعية بتقنية التسلسل الجيني من الجيل التالي تغطية جينية شاملة وموثوقة للتشخيص الدقيق وتحديد عوامل الخطورة الوراثية والطفرات القابلة للاستهداف علاجياً، وفقاً لأحدث إرشادات هيئة الصحة بدبي لعام 2026.
Overview: Clinical-Grade Myeloid Malignancy Profiling
The Myeloid Tumor Panel Genetic Test is a comprehensive next-generation sequencing assay designed to detect somatic and germline mutations across 37 critical genes, including ASXL1, TP53, FLT3, and RUNX1, implicated in myeloid malignancies. This test provides a definitive molecular classification of Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Myeloproliferative Neoplasms (MPN) to guide personalized targeted therapy selection and minimal residual disease monitoring according to 2026 DHA Precision Medicine mandates.
يقوم هذا الاختبار الجيني المتقدم بتحليل الحمض النووي لتحديد الطفرات الجينية المحددة في نخاع العظم، مما يمكّن أطباء الأورام من وضع خطة علاجية مخصصة ودقيقة وفقاً لأحدث البروتوكولات العالمية.
| Test Parameter | Our Test: Myeloid Panel NGS | Closest Alternative: Single-Gene PCR |
|---|---|---|
| Methodology | Advanced NGS (Liquid-Phase Capture + Bioinformatics Pipeline) | Quantitative Real-Time PCR |
| Genes Analyzed | 37 Genes (Comprehensive Multi-Gene Panel) | 1-3 Genes (Limited Scope) |
| Variant Detection | SNVs, Indels, CNVs (Broad Genomic Coverage) | Specific Known Mutations Only |
| Turnaround Time | 3 to 4 Weeks (Definitive Comprehensive Report) | 1-2 Weeks (Requires Follow-up Reflex Testing) |
Clinical Leadership & Physician Insight
"As a practicing hematopathologist, I emphasize that this panel is not merely a test but a navigational tool for the complex landscape of myeloid neoplasms. We must interpret the presence of mutations like TET2 or DNMT3A with strict clinical correlation, as they can sometimes represent age-related clonal hematopoiesis of indeterminate potential (CHIP) rather than overt malignancy. My team and I ensure that every result is contextualized within your complete blood picture, and I urge patients to view this as a vital, though not solitary, piece of their diagnostic journey."
— Dr. PRABHAKAR REDDY, Specialist Pathologist & Molecular Geneticist (DHA License: 61713011)
Do not discontinue, modify, or change the dosage of any prescribed medication, including anticoagulants or chemotherapy agents, without explicit instruction from your treating consultant. This genetic test is for diagnostic and prognostic evaluation and must not be used to independently make acute therapeutic changes.
Patient Safety Shields: Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Hemodynamic instability requiring immediate critical care; active severe bleeding (WHO Grade ≥3) precluding safe phlebotomy; known skin integrity issues at the FTA card collection site.
- Emergency Red Flags (Seek Immediate Emergency Care, not a scheduled test): Sudden onset of uncontrollable bleeding, acute fever with rigors and neutropenia (Absolute Neutrophil Count < 0.5 x 10⁹/L), new-onset confusion, or shortness of breath at rest.
- Sample Integrity: Patients who have received a packed red blood cell or platelet transfusion within the 48 hours prior to collection should be noted, although it does not contraindicate the test for DNA extraction.
Patient FAQ & Clinical Guidance on Myeloid NGS Testing
Q: What specific genetic mutations does this panel detect, and why does it take 3-4 weeks?
This test analyzes 37 critical genes, including FLT3, IDH1/2, TP53, and SF3B1, which provide comprehensive diagnostic clarity for myeloid neoplasms. The exact turnaround time of 3-4 weeks is required because our methodology involves DNA extraction, complex library preparation, high-depth next-generation sequencing on certified platforms, and crucially, a multi-step bioinformatics pipeline followed by clinical variant curation by a Ph.D. molecular geneticist to filter out benign polymorphisms and confirm actionable mutations.
س: ما هي الطفرات الجينية المحددة التي تكتشفها هذه اللوحة، وما أهمية مدة 3-4 أسابيع؟
ج: تقوم اللوحة بتحليل 37 جيناً محدداً منها FLT3 و TP53 بدقة تشخيصية عالية، والمدة الزمنية البالغة 3-4 أسابيع ضرورية لضمان تحليل المعلوماتية الحيوية المتقدم والتفسير السريري الدقيق.
Q: Can I use an FTA card for home collection, and will it affect the test's diagnostic sensitivity?
Yes, we accept one drop of blood on a specialized FTA card, which immediately stabilizes DNA at ambient temperature for transport. This method yields highly purified genomic DNA suitable for NGS, and our internal validation studies confirm it maintains >99% sensitivity compared to standard venipuncture into EDTA tubes, provided the collection procedure is followed correctly during our VIP Home Phlebotomy service. This is the preferred method for international or remote patients.
س: هل يمكن استخدام بطاقة FTA للجمع المنزلي، وهل تؤثر على حساسية الاختبار؟
ج: نعم، تقنية بطاقة FTA مقبولة ومعتمدة وتوفر استقراراً ممتازاً للحمض النووي، حيث تحافظ على حساسية تشخيصية تتجاوز 99% عند إجرائها بواسطة فريق التمريض المتنقل.
Q: How does this comply with UAE's strict 2026 data privacy and genetic laws?
Your genomic data is fully anonymized, encrypted, and processed on-shore in accordance with UAE Federal PDPL and the Genetic Testing provisions of CDS Law 2026. We strictly adhere to Federal Decree-Law No. 41 of 2024 (Art. 87) regarding the confidentiality of medical data. Genomic information is never shared with employers or insurance providers without a court order, and for minors, explicit mandatory consent following the 2026 Child Digital Safety (CDS) Law is stringently documented.
س: كيف يلتزم هذا الاختبار بقوانين الخصوصية الجينية الصارمة في الإمارات لعام 2026؟
ج: تتم معالجة بياناتكم الجينية بسرية تامة ومشفرة داخل الدولة وفقاً لقانون حماية البيانات الشخصية الفيدرالي والمرسوم بقانون اتحادي رقم 41 لعام 2024.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians